Strategies on the Development of Small Molecule Anticancer Drugs for Targeted Therapy

Lu, Y.-H.; Gao, X.-Q.; Wu, M.; Zhang-Negrerie, D.; Gao, Q.
June 2011
Mini Reviews in Medicinal Chemistry;Jun2011, Vol. 11 Issue 7, p611
Academic Journal
No abstract available.


Related Articles

  • Hematological malignancies: evolving the lifeblood of future pharmacotherapy.  // PharmaWatch: Monthly Review;Jul2005, Vol. 4 Issue 7, p10 

    The article investigates the potential therapeutic benefits of Glivec, a novel antineoplastic agent for hematological malignancies developed by Novartis SA. The novel agent was thought to be the start of a new era in cancer drug design, as it targets the specific molecular abnormality that...

  • The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy. Marin, Jose JG; Monte, Maria J; Blazquez, Alba G; Macias, Rocio IR; Serrano, Maria A; Briz, Oscar // Acta Pharmacologica Sinica;Jan2014, Vol. 35 Issue 1, p1 

    A major difficulty in the treatment of cancers is the poor response of many tumors to pharmacological regimens. This situation can be accounted for by the existence of a variety of complex mechanisms of chemoresistance (MOCs), leading to reduced intracellular concentrations of active agents,...

  • Macrocyclic Proteasome Inhibitors. Krahn, D.; Ottmann, C.; Kaiser, M. // Current Medicinal Chemistry;Nov2011, Vol. 18 Issue 33, p5052 

    Proteasome inhibitors have proven to be effective anticancer agents. Despite the success of the first on the market proteasome inhibitor bortezomib in chemotherapy, alternative clinically useful proteasome inhibitors are still urgently needed as bortezomib therapy causes severe side effects and...

  • Standardization of Dasana-Samasarkara Curna -A Polyherbal Ayurvedic Formulation. Tripathi, Manoj; Dwivedi, Neelesh; Tiwari, Ashok // International Journal of Pharmacy & Life Sciences;Sep2014, Vol. 5 Issue 9, p3840 

    The cancer disease has created a great demand for the discovery and development of new drug molecules. The major problem with the cancer chemotherapeutics is the toxicity by the current existing anti cancer drugs and anti tumor drug resistance by the cancerous cells to the anticancer agents....

  • Recent Developments in Anti-Cancer Agents Targeting PI3K, Akt and mTORC1/2. Dienstmann, Rodrigo; Rodon, Jordi; Markman, Ben; Tabernero, Josep // Recent Patents on Anti-Cancer Drug Discovery;May2011, Vol. 6 Issue 2, p210 

    Inappropriate PI3K signaling is one of the most frequent occurrences in human cancer and is critical for tumor progression. A variety of genetic mutations and amplifications have been described affecting key components of this pathway, with implications not only for tumorigenesis but also for...

  • DNA Topoisomerase II Enzymes as Molecular Targets for Cancer Chemotherapy. Chikamori, K.; Grozav, A. G.; Kozuki, T.; Grabowski, D.; Ganapathi, R.; Ganapathi, M. K. // Current Cancer Drug Targets;Nov2010, Vol. 10 Issue 7, p758 

    No abstract available.

  • Targeting the Hedgehog Pathway: The development of Cyclopamine and the Development of Anti-Cancer Drugs Targeting the Hedgehog Pathway. Gould, A.; Missailidis, S. // Mini Reviews in Medicinal Chemistry;Mar2011, Vol. 11 Issue 3, p200 

    No abstract available.

  • Sphaeropsidin A shows promising activity against drug-resistant cancer cells by targeting regulatory volume increase. Mathieu, Véronique; Chantôme, Aurélie; Lefranc, Florence; Cimmino, Alessio; Miklos, Walter; Paulitschke, Verena; Mohr, Thomas; Maddau, Lucia; Kornienko, Alexander; Berger, Walter; Vandier, Christophe; Evidente, Antonio; Delpire, Eric; Kiss, Robert // Cellular & Molecular Life Sciences;Oct2015, Vol. 72 Issue 19, p3731 

    Despite the recent advances in the treatment of tumors with intrinsic chemotherapy resistance, such as melanoma and renal cancers, their prognosis remains poor and new chemical agents with promising activity against these cancers are urgently needed. Sphaeropsidin A, a fungal metabolite whose...

  • Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy†. Damaraju, Vijaya L; Damaraju, Sambasivarao; Young, James D; Baldwin, Stephen A; Mackey, John; Sawyer, Michael B; Cass, Carol E // Oncogene;10/20/2003 Review 6, Vol. 22 Issue 47, p7524 

    The clinical efficacy of anticancer nucleoside drugs depends on a complex interplay of transporters mediating entry of nucleoside drugs into cells, efflux mechanisms that remove drugs from intracellular compartments and cellular metabolism to active metabolites. Nucleoside transporters (NTs) are...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics